EANM procedure guidelines for brain neurotransmission SPECT/PET using dopamine D2 receptor ligands, version 2

被引：0
作者：
Koen Van Laere
Andrea Varrone
Jan Booij
Thierry Vander Borght
Flavio Nobili
Özlem L. Kapucu
Zuzana Walker
Kjell Någren
Klaus Tatsch
Jacques Darcourt
机构：
[1] University Hospital Leuven,Division of Nuclear Medicine
[2] Karolinska Institute,Department of Clinical Neuroscience, Psychiatry Section
[3] University of Amsterdam,Department of Nuclear Medicine, Academic Medical Center
[4] Université Catholique de Louvain,Nuclear Medicine Division
[5] Mont-Godinne Medical Center,Clinical Neurophysiology Unit, San Martino Hospital
[6] University of Genoa,Department of Nuclear Medicine
[7] Gazi University,Psychiatry, Department of Mental Health Sciences
[8] University College London,Rigshospitalet
[9] Copenhagen University Hospital,Department of Nuclear Medicine
[10] Municipal Hospital of Karlsruhe Inc,Nuclear Medicine Division
[11] Centre Antoine Lacassagne and University Hospital,undefined
[12] Université de Nice Sophia Antipolis,undefined
来源：
European Journal of Nuclear Medicine and Molecular Imaging | 2010年 / 37卷
关键词：
Brain; Dopamine; D2 receptor; SPECT; PET; Parkinsonism;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The guidelines summarize the current views of the European Association of Nuclear Medicine Neuroimaging Committee (ENC). The aims of the guidelines are to assist nuclear medicine practitioners in making recommendations, performing, interpreting and reporting the results of clinical dopamine D2 receptor SPECT or PET studies, and to achieve a high quality standard of dopamine D2 receptor imaging, which will increase the impact of this technique in neurological practice.
引用
收藏
页码：434 / 442
页数：8
相关论文
共 122 条
[1]  
Tatsch K(2002)European Association of Nuclear Medicine procedure guidelines for brain neurotransmission SPET using (123)I-labelled dopamine transporter ligands Eur J Nucl Med Mol Imaging 29 BP30-BP35
[2]  
Asenbaum S(1996)Ethical clinical practice of functional brain imaging J Nucl Med 37 1256-1259
[3]  
Bartenstein P(2006)PET tracers for imaging of the dopaminergic system Curr Med Chem 13 2139-2153
[4]  
Elsinga PH(1995)Fluorinated benzamide neuroleptics--III. Development of (S)-N-[(1-allyl-2-pyrrolidinyl)methyl]-5-(3-[18F]fluoropropyl)-2,3-dimethoxybenzamide as an improved dopamine D-2 receptor tracer Nucl Med Biol 22 283-296
[5]  
Hatano K(2004)The dopamine D2 receptor ligand 18F-desmethoxyfallypride: an appropriate fluorinated PET tracer for the differential diagnosis of parkinsonism Eur J Nucl Med Mol Imaging 31 1128-1135
[6]  
Ishiwata K(1985)Substituted benzamides as ligands for visualization of dopamine receptor binding in the human brain by positron emission tomography Proc Natl Acad Sci U S A 82 3863-3867
[7]  
Mukherjee J(2006)Applications of clinical dopamine imaging Neuroimaging Clin N Am 16 553-573
[8]  
Yang ZY(2005)The role of radiotracer imaging in Parkinson disease Neurology 64 208-215
[9]  
Das MK(2004)PET and SPECT functional imaging studies in Parkinsonian syndromes: from the lesion to its consequences Neuroimage 23 1-16
[10]  
Brown T(2007)SPECT imaging of the dopaminergic system in (premotor) Parkinson’s disease Parkinsonism Relat Disord 13 S425-S428
12345678910